True Wealth Design’s BioMarin Pharmaceuticals BMRN Stock Holding History

True Wealth Design’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.8K	Sell	957 -695	-42%	-$38.1K	0.01%	456
2026 Q1	$93.3K	Buy	1,652 +384	+30%	+$22.4K	0.03%	230
2025 Q4	$75.4K	Sell	1,268 -717	-36%	-$39K	0.02%	233
2025 Q3	$108K	Buy	1,985 +1,609	+428%	+$92K	0.03%	148
2025 Q2	$20.7K	Sell	376 -969	-72%	-$57.1K	0.01%	377
2025 Q1	$95.1K	Buy	1,345 +1,239	+1,169%	+$83.4K	0.04%	101
2024 Q4	$6.97K	Sell	106 -704	-87%	-$47.2K	﹤0.01%	474
2024 Q3	$56.9K	Buy	810 +804	+13,400%	+$67.2K	0.02%	120
2024 Q2	$494	Hold	6	–	–	﹤0.01%	654
2024 Q1	$525	Buy	6 +2	+50%	+$179	﹤0.01%	613
2023 Q4	$386	Hold	4	–	–	﹤0.01%	543
2023 Q3	$354	Hold	4	–	–	﹤0.01%	515
2023 Q2	$347	Hold	4	–	–	﹤0.01%	547
2023 Q1	$389	Hold	4	–	–	﹤0.01%	586
2022 Q4	$414	Buy	+4	New	+$376	﹤0.01%	505

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

True Wealth Design's BMRN Position: Q2 2026 in Review

True Wealth Design reduced its BioMarin Pharmaceuticals (BMRN) stake by 42% in Q2 2026, selling an estimated $38.1K and leaving 957 shares worth $54.8K. The position accounts for 0.01% of the portfolio, ranked #456.

True Wealth Design first reported a position in BMRN in Q4 2022 and has held it in 15 quarters since. The position peaked at $108K in Q3 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

True Wealth Design held 957 shares of BioMarin Pharmaceuticals worth $54.8K as of Q2 2026.
True Wealth Design sold 695 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $38.1K.
BioMarin Pharmaceuticals made up 0.01% of True Wealth Design's portfolio in Q2 2026, its #456 holding.
True Wealth Design first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
True Wealth Design's BioMarin Pharmaceuticals position peaked at $108K in Q3 2025.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.